[ Price : $8.95]
Former FDA commissioner Scott Gottlieb predicts just-confirmed FDA commissioner Marty Makary will soon face political interference...[ Price : $8.95]
BeiGene scraps the development of BGB-A1217 (ociperlimab), an anti-TIGIT antibody, as a potential treatment for lung cancer.[ Price : $8.95]
FDAs accelerated approval program faces renewed scrutiny after a recent JAMA study highlighted concerns about cancer drugs that re...[ Price : $8.95]
Biogen wins a fast-track designation for BIIB080, an investigational antisense oligonucleotide therapy for treating Alzheimers dis...[ Price : $8.95]
Former FDA commissioner Mark McClellan says it will be a challenge for the agency to come through the massive reorganization and s...[ Price : $8.95]
Industry associations sound alarms and frustrations as they weigh how FDA staff cuts will impact product development, FDA reviews ...[ Price : $8.95]
Roche says the Phase 3 MUSETTE study found that a higher dose of Ocrevus IV did not provide more benefit than the approved 600 mg ...[ Price : $8.95]
Edgewise Therapeutics says its EDG-7500 achieved positive results in the four-week CIRRUS-HCM trial in hypertrophic cardiomyopathy...